Dishman Carbogen Amcis Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2022 • CRAMS: 77.0% • Vitamin-D, Bulk Drugs, Quats, Speciality Chemicals and traded goods: 23.0%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company generates healthy free cash flow
- Company maintains a comfortable, low leverage position
CONS
- A large part of profit comes from other income (263.5% of PBT)
- Recent results are weak - TTM profit is down 87.8% versus prior year
- Receivables are growing faster than sales - a possible quality concern
- Company has a low return on capital employed of 0.9%
- Company has a low return on equity of -1.1% over last 3 years
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -5.67x)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| DCAL | 167.30 | 162.31 | 2622.98 | 0.00 | -57.88 | -347.24 | 677.64 | -4.29 | 2.31 | 8.87 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 723 | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 | 653 | 720 | 851 | 678 | |
| 602 | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 | 504 | 607 | 688 | 745 | |
| Operating Profit | 122 | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 | 149 | 113 | 163 | -68 |
| OPM % | 16.85% | 10.37% | 6.31% | 9.57% | 5.53% | 18.65% | 20.54% | 21.32% | 19.87% | 22.81% | 15.71% | 19.14% | -9.99% |
| 7 | 5 | 6 | 4 | -4 | 4 | 8 | -4 | 22 | 8 | 7 | 15 | 20 | |
| Interest | 28 | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 | 42 | 46 | 43 | 37 |
| Depreciation | 70 | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 | 84 | 84 | 89 | 91 |
| Profit before Tax | 29 | -36 | -66 | -49 | -78 | 42 | 27 | 28 | 39 | 31 | -10 | 46 | -51 |
| Tax % | 42.35% | -12.80% | 10.05% | -42.11% | -0.01% | 21.44% | 82.88% | -55.56% | 39.46% | -113.72% | -24.23% | 52.87% | -13.00% |
| Net Profit | 0 | 0 | 0 | 0 | -78 | 33 | 5 | 43 | 23 | 65 | -13 | 22 | -58 |
| 1.08 | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 | 1.49 | 4.16 | -0.83 | 1.39 | -3.69 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,714 | 1,695 | 2,059 | 2,044 | 1,912 | 2,141 | 2,413 | 2,616 | 2,712 | 2,901 | |
| 1,260 | 1,257 | 1,507 | 1,546 | 1,638 | 1,815 | 2,081 | 2,352 | 2,272 | 2,544 | |
| Operating Profit | 453 | 438 | 552 | 498 | 274 | 326 | 332 | 264 | 440 | 357 |
| OPM % | 26.45% | 25.85% | 26.81% | 24.35% | 14.34% | 15.21% | 13.77% | 10.09% | 16.22% | 12.31% |
| 26 | 53 | 54 | 44 | 16 | 34 | -20 | 45 | 33 | 50 | |
| Interest | 49 | 49 | 57 | 62 | 48 | 57 | 86 | 120 | 159 | 169 |
| Depreciation | 214 | 211 | 240 | 283 | 308 | 308 | 281 | 311 | 294 | 348 |
| Profit before Tax | 216 | 231 | 309 | 197 | -65 | -4 | -55 | -122 | 19 | 15 |
| Tax % | 32.70% | 33.03% | 31.89% | 19.62% | -153.93% | 523.76% | 45.41% | -25.51% | 83.22% | -7.66% |
| Net Profit | 145 | 155 | 210 | 159 | -165 | 18 | -30 | -153 | 3 | 16 |
| EPS | 9.01 | 9.58 | 13.03 | 10.10 | -10.53 | 1.15 | -1.90 | -9.79 | 0.21 | — |
| Dividend Payout % | — | 0.00% | 1.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 6%
- 3 Years:
- 8%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- -54%
- 3 Years:
- -44%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- -4%
- 3 Years:
- 3%
- 1 Year:
- -38%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- -1%
- 3 Years:
- -1%
- Last Year:
- 0%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0 | 32 | 32 | 31 | 31 | 31 | 31 | 31 | 31 |
| 4 | 5,075 | 5,347 | 5,684 | 5,667 | 5,518 | 5,778 | 5,596 | 5,800 | |
| 850 | 918 | 883 | 1,165 | 1,417 | 1,756 | 2,218 | 2,601 | 2,534 | |
| Trade Payables | 86 | 186 | 195 | 284 | 169 | 193 | 220 | 244 | 231 |
| 5,635 | 957 | 864 | 1,029 | 1,071 | 1,136 | 1,192 | 1,098 | 1,391 | |
| Total Liabilities | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 9,986 |
| 4,847 | 5,061 | 5,092 | 5,673 | 5,693 | 5,768 | 6,183 | 6,720 | 7,051 | |
| Capital Work in Progress | 122 | 119 | 143 | 202 | 425 | 755 | 996 | 501 | 252 |
| 40 | 196 | 167 | 191 | 172 | 324 | 249 | 102 | 97 | |
| 427 | 485 | 549 | 581 | 516 | 645 | 804 | 883 | 900 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 484 | 665 | |
| Cash & Bank | 87 | 69 | 96 | 161 | 308 | 172 | 189 | 413 | 507 |
| 1,052 | 1,240 | 1,273 | 1,386 | 1,242 | 970 | 1,018 | 467 | 514 | |
| Total Assets | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 9,986 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| 418 | 260 | 412 | 660 | 564 | 411 | 300 | 379 | 375 | |
| Cash from Investing | -142 | -297 | -169 | -442 | -380 | -619 | -494 | -230 | -192 |
| Cash from Financing | -137 | 78 | -102 | -98 | -11 | 130 | 250 | -22 | -102 |
| 23 | 7 | 11 | 46 | 122 | -133 | 22 | 128 | 81 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-12 - Dishman Carbogen Amcis Limited has informed the Exchange about General Updates
2026-09-07 - Dishman Carbogen Amcis Limited has informed the Exchange about Copy of Newspaper Publication regarding intimation of 19th AGM and E-Voting Instructions.
2026-09-05 - Dishman Carbogen Amcis Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026
2026-09-02 - Dishman Carbogen Amcis Limited has informed the Exchange about Copy of Newspaper Publication for intimation regarding 19th AGM to be held through Video Conferencing or Other Audio Visual Means.
2026-08-31 - Dishman Carbogen Amcis Limited has informed the Exchange regarding 'Intimation regarding date of 19th Annual General Meeting'.
2026-08-29 - Dishman Carbogen Amcis Limited has informed the Exchange regarding Cessation of Mr Deepak Ram Chandra Mittal as Other of the company w.e.f. August 27, 2026.
2026-08-21 - Dishman Carbogen Amcis Limited has informed the Exchange about Transcript
2026-08-17 - Dishman Carbogen Amcis Limited has informed the Exchange about Link of Recording
2026-08-17 - Dishman Carbogen Amcis Limited has informed the Exchange regarding allotment of 7500 securities pursuant to Non Convertible Securities at its meeting held on August 17, 2026
News
Recent coverage and analyst commentary for DCAL
Loading news…
AI Stock Analyst
Dishman Carbogen Amcis Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account